恩替卡韦治疗慢性乙型肝炎临床疗效及安全性分析

目的探讨恩替卡韦（ETV）治疗慢性乙型肝炎临床疗效及安全性。方法将80例慢性乙肝患者按照抽签方法随机均分为对照组与观察组，各为40例。观察组给予0．5mg／d的ETV治疗，对照组给予100mg／d的拉米夫定（LAM）治疗。比较二组治疗前后肝功能指标变化、超声影像学指标变化、治疗后HBV—DNA滴度与转阴率、不良反应。结果①二组治疗前后肝功能指标（ALT、ALB及TBiD相比，差异均具有统计学意义（P〈0．05，P〈0．01），且二组治疗后上述指标差异也均具有统计学意义（P〈0．05）；②二组治疗后超声影像学指标相比，差异均具有统计学意义（P〈0．05），但二组治疗后超声影像学指标相比，差异均无统计学意义（P均〉0．05）；③二组治疗前后HBV—DNA滴度相比，差异均具有统计学意义（P〈0．05），且二组治疗后HBV—DNA滴度相比，差异也具有统计学意义（P〈0．05）；观察组治疗后HBV—DNA转阴率为90．00％，显著高于对照组（72．50％）（P〈0．05）；④二组治疗过程中均未见不良反应发生。结论与LAM相比，ETV治疗慢性乙肝疗效更为显著，安全性高，应在临床上进行推广及应用。

EFFICACY AND SAFETY OF ENTECAVIR IN TREATMENT OF CHRONIC HEPATITIS B

Objective To investigate the efficacy and safety of entecavir （ETV） in treatment of chronic hep- atitis B. Methods A total of 80 patients with chronic hepatitis B were divided into control group and ob- servation group with a simple drawing random, each with 40 cases. Observation group received 0.5mg / d of ETV, the control group was given 100mg / d of lamivudine （LAM）. Changes in liver function, ultra- sound imaging index were compared before and after treatment, HBV- DNA titers, the negative rate and adverse reactions rate were compared after treatment. Results The difference of liver function（ALT, ALB and TBil） in the two groups was statistically significant before and after treatment（P〈0.05,P〈 0.01 ）, and the difference between the two groups after the treatment of these indicators was also statisti- cally significance { P〈0.05）. After treatment, the difference of ultrasound imaging indicators were statis- tically significant between the two groups（P〈0.05）, but tultrasound imaging indicators were no statistical difference （P〈0.05）. There was statistically difference of HBV- DNA titers before and after treatment （P〈0.05）, and it was also same as between the two groups （P〈0.05）. The HBV- DNA negative rate after treatment in observation group was 90.00%, which was significantly higher than that in the control group （72.50%） （P〈0.05）. During the treatment, both groups showed no adverse reactions. Conclusion Compared with LAM, ETV in treatment of chronic hepatitis B has more significant effect and safety, which worthy the promotion and application in clinical practice.